I 
118TH CONGRESS 
2D SESSION 
H. R. 7155 
To provide for the establishment, within the Food and Drug Administration, 
of an Abraham Accords Bureau to promote and facilitate cooperation 
between the Food and Drug Administration and entities in Abraham 
Accords countries wishing to work with the agency in order to develop 
and sell products in the United States, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 31, 2024 
Mrs. HARSHBARGER (for herself, Mr. VARGAS, Mr. WEBER of Texas, Mr. 
PETERS, Mr. HARRIS, Mr. LEVIN, and Mr. ALLEN) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce 
A BILL 
To provide for the establishment, within the Food and Drug 
Administration, of an Abraham Accords Bureau to pro-
mote and facilitate cooperation between the Food and 
Drug Administration and entities in Abraham Accords 
countries wishing to work with the agency in order to 
develop and sell products in the United States, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
VerDate Sep 11 2014 
21:40 Feb 05, 2024
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7155.IH
H7155
ssavage on LAPJG3WLY3PROD with BILLS
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘United States-Abra-
ham Accords Cooperation and Security Act of 2024’’. 
SEC. 2. ESTABLISHMENT OF ABRAHAM ACCORDS BUREAU 
WITHIN FOOD AND DRUG ADMINISTRATION. 
(a) IN GENERAL.—Chapter X of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 391 et seq.) is amend-
ed by adding at the end the following: 
‘‘SEC. 1015. ABRAHAM ACCORDS BUREAU. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Commissioner of Food and Drugs, shall establish with-
in the Food and Drug Administration a bureau, to be 
known as the Abraham Accords Bureau, to be headed by 
a director. 
‘‘(b) OFFICES.—Not later than one year after the 
date of enactment of this section, the Secretary shall— 
‘‘(1) in consultation with the governments of 
Abraham Accords countries— 
‘‘(A) select the locations of one or more of-
fices of the Abraham Accords Bureau in one or 
more Abraham Accords countries; and 
‘‘(B) establish each such office; and 
‘‘(2) assign to each such office such personnel 
of the Food and Drug Administration as the Sec-
retary determines necessary to carry out the func-
tions of the office. 
VerDate Sep 11 2014 
21:40 Feb 05, 2024
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H7155.IH
H7155
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(c) DUTIES.—The Secretary, acting through the Di-
rector of the Abraham Accords Bureau, shall— 
‘‘(1) not later than 90 days after all offices of 
the Abraham Accords Bureau are established— 
‘‘(A) develop a list of essential medical, 
biomedical, and life sciences products, the key 
raw pharmaceutical ingredients of such prod-
ucts, and the active pharmaceutical ingredients 
of such products, that are primarily manufac-
tured in a covered country; 
‘‘(B) develop a list of medical, biomedical, 
and life sciences facilities and entities in Abra-
ham Accord countries that can engage with of-
fices of the Abraham Accords Bureau to bolster 
the United States’ health care and medical sup-
ply needs; and 
‘‘(C) submit such lists to the Congress; 
‘‘(2) not less than every 3 years thereafter, up-
date the lists under paragraph (1) and submit the 
updated lists to the Congress; 
‘‘(3) consult with parties in Abraham Accords 
countries on good manufacturing practices and other 
issues relevant to manufacturing medical products 
that are regulated by the Food and Drug Adminis-
tration; 
VerDate Sep 11 2014 
21:40 Feb 05, 2024
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H7155.IH
H7155
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(4) facilitate interactions between the Food 
and Drug Administration and interested parties in 
Abraham Accords countries, including by sharing 
relevant information regarding United States regu-
latory pathways with such parties; 
‘‘(5) offer technical assistance on manufac-
turing drugs and devices to interested parties in 
Abraham Accords countries; and 
‘‘(6) carry out other functions and activities as 
the Secretary determines to be necessary to carry 
out this section. 
‘‘(d) LIMITATION.—Notwithstanding any other provi-
sion of this section, this section does not authorize any 
assistance to any entity in an Abrahams Accords country 
that, for purposes of manufacturing, uses any ingredient 
or product that is produced or manufactured in a covered 
country. 
‘‘(e) DEFINITIONS.—In this section: 
‘‘(1) The term ‘Abraham Accords country’ 
means a country identified by the Department of 
State as having signed the Abraham Accords Dec-
laration. 
‘‘(2) The term ‘covered country’ means a coun-
try— 
VerDate Sep 11 2014 
21:40 Feb 05, 2024
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H7155.IH
H7155
ssavage on LAPJG3WLY3PROD with BILLS
‘‘(A) designated as a country of particular 
concern for religious freedom under section 
402(b)(1)(A)(ii) of the International Religious 
Freedom Act of 1998; or 
‘‘(B) the government of which engages in 
a consistent pattern of gross violations of inter-
nationally recognized human rights, as defined 
in section 502B(d)(1) of the Foreign Assistance 
Act of 1961. 
‘‘(3) The term ‘essential medical products’ shall 
have such definition as the Secretary may determine 
for purposes of this section. 
‘‘(4) The term ‘primarily manufactured in a 
covered country’ means— 
‘‘(A) manufactured in a covered country in 
final form; or 
‘‘(B) containing any active pharmaceutical 
ingredient or excipient that was manufactured 
in a covered country.’’. 
(b) REPORT TO CONGRESS.—Not later than 3 years 
after the date of enactment of this Act, the Secretary of 
Health and Human Services shall submit to the Congress 
a report on the Abraham Accords Bureau, including— 
(1) an evaluation of— 
VerDate Sep 11 2014 
21:40 Feb 05, 2024
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H7155.IH
H7155
ssavage on LAPJG3WLY3PROD with BILLS
(A) how each office of the Bureau has ad-
vanced progress toward shifting United States 
supply chains of essential medical products 
from covered countries to Abraham Accords 
countries (as such terms are defined in section 
1015 of the Federal Food, Drug, and Cosmetic 
Act, as added by subsection (a)); and 
(B) the effectiveness of the activities car-
ried out pursuant to section 1015(c) of the 
Federal Food, Drug, and Cosmetic Act, as 
added by subsection (a); and 
(2) recommendations for increasing and improv-
ing coordination between the Food and Drug Admin-
istration and entities in Abraham Accords countries 
(as such term is defined in section 1015 of the Fed-
eral Food, Drug, and Cosmetic Act, as added by 
subsection (a)). 
Æ 
VerDate Sep 11 2014 
21:40 Feb 05, 2024
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6301
E:\BILLS\H7155.IH
H7155
ssavage on LAPJG3WLY3PROD with BILLS